Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan

Hozumi Kumagai, Hitoshi Kusaba, Yuta Okumura, Masato Komoda, Michitaka Nakano, Shingo Tamura, Mayako Uchida, Kenichiro Nagata, Shuji Arita, Hiroshi Ariyama, Shigeo Takaishi, Koichi Akashi, Eishi Baba

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

Original languageEnglish
Pages (from-to)461-465
Number of pages5
JournalAsian Pacific Journal of Cancer Prevention
Volume15
Issue number1
DOIs
Publication statusPublished - 2014

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan'. Together they form a unique fingerprint.

Cite this